EMERYVILLE, Calif., June 23, 2022 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the global transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that she had successfully started fermentation in her new precision fermentation plant in Barra Bonita, Brazil.

Amyris Logo (PRNewsfoto/Amyris, Inc.)

The Barra Bonita greenfield site makes Amyris the leading manufacturer of highly engineered, industrial-scale bodies. First-of-its-kind precision fermentation plant is a strategic investment made to meet the growing demand for clean, sustainable, chemistry-based products for the beauty, personal care, health and wellness markets .

The plant consists of five precision fermentation “mini-factories” capable of simultaneously producing the 13 molecules of Amyris currently on the market as well as future bio-fermented products. The plant’s capacity is fully committed until the end of 2023 with the production of natural vanillin, sugarcane-based Reb M, squalane, squalene, hemisqualene and patchouli as well as others molecules. The plant will allow Amyris to more effectively meet customer demand for ingredients after several years of operating under third party capacity supply constraints.

“The commissioning and start-up of our Barra Bonita plant is an important milestone for Amyris. I am very proud of the team who designed and built our new factory in record time and during an unprecedented pandemic,” said Eduardo Alvarez, Deputy Chief Executive Officer of Amyris. “Our team has delivered the world’s first precision fermentation facility for the production of natural products using highly technical organisms. More than 800 people have played an important role in the success of this project. We are very pleased to leverage this state-of-the-art in-house manufacturing facility allowing us to respond more effectively to customer demand in the future.”

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the proprietary Lab-to-Market™ technology platform of the society. This Amyris platform leverages cutting-edge machine learning, robotics and artificial intelligence, enabling the company to quickly bring new innovations to market at commercial scale. Amyris ingredients are included in more than 20,000 products from the world’s leading brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that are constantly evolving to meet the growing demand for durable, efficient and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo, and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the United States and/or other countries.

Forward-looking statements

This press release contains forward-looking statements, and any statements other than statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris’ ability to meet growing customer demand through its new Barra Bonita facility and Amyris’ expectations regarding production capacity and commitments through 2023. These statements are based on current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks relating to Amyris’ liquidity and its ability to fund operating and capital expenditures, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures of development, regulatory approval, launch, production and commercialization of products, risks related to the COVID-19 pandemic and to t any other geopolitical event, including Russia’s invasion of Ukraine, resulting in a global economic crisis, financial and supply chain disruptions which may negate materially impact business operations and financial results of Amyris or result in market volatility, risks relating to Amyris’ reliance on third parties, particularly in the supply chain, and other risks detailed from time to time in Amyris’ filings with from the Securities and Exchange Commission, including Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Amyris disclaims any obligation to update the information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.



Show original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-barra-bonita-fermentation-plant-begins-industrial-production-301573994.html

SOURCEAmyris, Inc.